In view of the strong demand, the price range had to be increased twice and the price could finally be fixed at CHF 39. After the exercise of the over-allotment option (Greenshoe), the free float will amount to 100% and Galenica as the Selling Shareholder will hold only some rump shares for exchange. The market capitalization amounts to abound CHF 1.9 billion. Thus, YTD 2017 it is the largest IPO in Europe and the second largest IPO worldwide.
Kellerhals Carrard in its capacity as lead counsel to the transaction (lead: Dr. B. Brechbühl; co-Lead: Dr. Ch. Witschi; team members: Dr. E. Dettwiler, Dr. E. Philippin, I. Pöschel, Ph. Frésard, K. Enderli, A. Schütz, S. Holdt, S. Brütsch and C. Castellote) coordinated the other legal teams, advised and supported Galenica and Galenica Santé in transactional, capital markets, corporate and regulatory issue including support in drafting documents (i.e prospectus) and negotiation of the agreements with the banks.